However, these medications are not FDA-approved, so buyer beware. The competing GLP-1 drug tirzepatide (Mounjaro, Zepbound) is similarly branded by a single company, Cutler continued
Notably, the oral version is only approved for diabetes, not weight loss, and may cause more gastrointestinal side effects
New GLP-1 Clinical Study Finds Calocurb Reduces Body Weight and Body Fat Without Loss of Muscle Mass The natural GLP-1 activator is clinically shown to support fat loss, including visceral fat reduction, while preserving lean muscle AUCKLAND, New Zealand, July 23, 2026 --(BUSINESS WIRE)--Calocurb, the New Zealand-based company bringing the world the first 100% natural GLP-1 activator, announces today the publication of a new clinical study in US medical journal, Obesity Pillars, demonstrating Calocurb's effectiveness in weight loss and muscle preservation
Structural Basis for GLP-1 Receptor Activation by LY3502970, an Orally Active Nonpeptide Agonist
GLP-1 Receptor Agonists for Obesity Management in Older Adults: A Scoping Review on the Risk of Sarcopenia and Sarcopenic Obesity
It uses advanced pharmaceutical technology to protect the peptide through the digestive tract, facilitate absorption into systemic circulation, and deliver a predictable, clinically effective dose
,aspect=ignore)
